| Literature DB >> 32726865 |
Guadalupe Sanchez1, Samuel C Linde1, Joseph D Coolon1.
Abstract
Tetracycline (Tet) and derivative chemicals (e.g., doxycycline or Dox) have gained widespread recognition for their antibiotic properties since their introduction in the late 1970s, but recent work with these chemicals in the lab has shifted to include multiple techniques in all genetic model systems for the precise control of gene expression. The most widely used Tet-modulated methodology is the Tet-On/Tet-Off gene expression system. Tet is generally considered to have effects specific to bacteria; therefore, it should have few off-target effects when used in eukaryotic systems, and a previous study in the yeast Saccharomyces cerevisiae found that Dox had no effect on genome-wide gene expression as measured by microarray. In contrast, another study found that the use of Dox in common cell lines and several model organisms led to mitonuclear protein imbalance, suggesting an inhibitory role of Dox in eukaryotic mitochondria. Recently, a new Dox derivative, 4-epidoxycycline (4-ED) was developed that was shown to have less off-target consequences on mitochondrial health. To determine the best tetracycline family chemical to use for gene expression control in S. cerevisiae, we performed RNA sequencing (RNA-seq) on yeast grown on standard medium compared with growth on media supplemented with Tet, Dox or 4-ED. We found each caused dozens of genes to change expression, with Dox eliciting the greatest expression responses, suggesting that the specific tetracycline used in experiments should be tailored to the specific gene(s) of interest when using the Tet-On/Tet-Off system to reduce the consequences of confounding off-target responses.Entities:
Keywords: RNA-seq; gene expression; tetracycline; yeast
Mesh:
Substances:
Year: 2020 PMID: 32726865 PMCID: PMC7540071 DOI: 10.1002/yea.3515
Source DB: PubMed Journal: Yeast ISSN: 0749-503X Impact factor: 3.239
FIGURE 1Experimental design and analysis pipeline. (a) The design of the experiment and sample collection is shown. (b) The bioinformatics pipeline used for RNA‐seq data processing and analysis is indicated
Total number of mapped reads for RNA‐seq libraries
| Sample | # reads | # mapping | % mapping |
|---|---|---|---|
| Control 1 | 37,276,053 | 36,560,731 | 98.1% |
| Control 2 | 40,352,284 | 39,439,313 | 97.7% |
| Control 3 | 41,194,014 | 40,314,390 | 97.9% |
| Dox 1 | 40,248,828 | 39,298,914 | 97.6% |
| Dox 2 | 31,976,734 | 31,251,336 | 97.7% |
| Dox 3 | 36,780,721 | 35,990,049 | 97.9% |
| Tet 1 | 32,333,060 | 31,676,304 | 97.9% |
| Tet 2 | 34,238,073 | 33,435,560 | 97.7% |
| Tet 3 | 31,962,937 | 31,128,128 | 97.4% |
| 4‐ED 1 | 37,632,247 | 36,713,336 | 97.6% |
| 4‐ED 2 | 38,027,360 | 37,232,697 | 97.9% |
| 4‐ED 3 | 36,925,262 | 35,885,918 | 97.2% |
FIGURE 2Identification of significantly expressed genes. (a,c,e) Scatterplots of all differentially expressed genes in Saccharomyces cerevisiae treated with 1.5 μg/ml of (a) Tet, (c) Dox and (e) 4‐ED in fragments per kilobase of transcript per million mapped reads (FPKM). (b,d,f) Volcano plots showing the magnitude of expression difference in control compared with treatments (b) Tet, (d) Dox and (f) 4‐ED on the x‐axis and −log10 transformed false discovery rate corrected p values (q‐values) on the y‐axis. (red = significant, black = non‐significant) [Colour figure can be viewed at wileyonlinelibrary.com]
Differentially expressed genes (DEGs) identified responding to treatment with Tet, Dox or 4‐ED
| Treatment | # DEG | # upregulated | # downregulated |
|---|---|---|---|
| Tet | 22 | 15 | 7 |
| Dox | 83 | 27 | 56 |
| 4‐ED | 58 | 38 | 20 |
FIGURE 3Overlap of genes identified as significantly differentially expressed in response to Tet, Dox and 4‐ED [Colour figure can be viewed at wileyonlinelibrary.com]
Overlap of genes identified as responding to Tet, Dox or 4‐ED treatments
| Genes in all three | Genes in Dox/Tet | Genes in Dox/4‐ED | Genes in Tet/4‐ED |
|---|---|---|---|
|
|
|
|
|